IP Library Granted Patent US 11,286,465
Granted Patent B2
US 11,286,465 · App. 16/230,990 · Granted Mar 29, 2022

ICP0-mediated enhanced expression system

Inventors: Simon Delagrave (Cambridge, MA); CharChang Lai (Cambridge, MA)
Assignee: SANOFI PASTEUR INC.
C12N7/00C12N2710/16622C12N2710/16634C12N2710/16651
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,286,465
App. No.
16/230,990
Granted
Mar 29, 2022
Kind
B2
Abstract

Methods and compositions for increasing the production of recombinant proteins by introducing ICP0 to cells capable of producing a recombinant protein are encompassed. In one method, the recombinant protein is a protein that is required for the replication of a replication defective virus, wherein the recombinant protein is provided to the replication defective virus in trans.

Claims (11)

1. A method of increasing heterologous recombinant protein expression from a viral promoter in vitro, comprising:

introducing by transfection a herpes simplex virus (HSV) infected cell polypeptide zero (ICP0) to a cell comprising a transgene encoding the heterologous protein operably linked to the viral promoter, wherein the cell is a mammalian cell and is capable of expressing the recombinant protein from the viral promoter; and

isolating the recombinant protein from the cell, wherein:

(i) the recombinant protein is non-viral; and/or

(ii) the ICP0 is introduced by transfection with a plasmid comprising a sequence encoding ICP0 operably linked to a CMV promoter, an SV40 promoter, or a non-inducible promoter comprising a TATA box, GC-box, CCAAT box, B recognition element, and an initiator element; the heterologous recombinant protein is heterologous relative to the cell; and the heterologous protein is expressed by 24 hours after introduction of ICP0.

2. The method of claim 1 , wherein the recombinant protein is an antibody, a vaccine antigen, a hormone, or an enzyme.

3. The method of claim 1 , wherein the recombinant protein is a mammalian protein.

4. The method of claim 1 , wherein the recombinant protein is non-viral.

5. The method of claim 1 , wherein the ICP0 is introduced by transfection with a plasmid encoding ICP0 and comprising a non-inducible promoter, and the non-inducible promoter is a CMV promoter, an SV40 promoter, or a promoter comprising a TATA box, GC-box, CCAAT box, B recognition element, and an initiator element.

6. The method of claim 1 , wherein the cell is a Vero, BHK, CHO, HKB, HEK, NSO and U-2 OS, WI-38, MRC-5, MDCK, FRhL-2, or PERC6 cell.

7. The method of claim 1 , wherein the cell is a Vero cell.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2021
From: DELAGRAVE, SIMON; LAI, CHARCHANG
To: SANOFI PASTEUR BIOLOGICS, LLC
Reel/Frame 058362/0937 →
MERGER Recorded Dec 10, 2021
From: SANOFI PASTEUR BIOLOGICS, LLC
To: SANOFI PASTEUR INC.
Reel/Frame 058362/0950 →
Continuity (3)
Continuation 15572890
Provisional Application 62161194 · May 13, 2015
Related Publication 20190194626A1 · Jun 27, 2019